Physician profile
Jonathan D Parkhurst
NPI 1164628889
$10,547.93
in general payments reported to CMS, 2019-2025
60 companies · $765 in 2025
The $765 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,697 · 2020: $1,853 · 2021: $11.56 · 2022: $1,275 · 2023: $2,544 · 2024: $1,402 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,590 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,589.79 |
| Education | $121.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,301.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,026.91 | 2019-2025 | |
| Glaxosmithkline, LLC. | $898.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $717.64 | 2019-2023 | |
| Pfizer INC. | $703.38 | 2019-2025 | |
| Lilly USA, LLC | $619.34 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.36 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $483.04 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $468.48 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $344.06 | 2019-2024 | Verquvo, Gardasil 9, Belsomra |
| Amgen INC. | $338.44 | 2019-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.47 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $256.60 | 2019-2025 | Trintellix, Gattex |
| Novartis Pharmaceuticals Corporation | $240.58 | 2019-2024 | |
| Astellas Pharma US INC | $227.97 | 2019-2024 | Veozah, Myrbetriq |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Parkhurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.